AR105593A1 - Agonistas muscarínicos - Google Patents
Agonistas muscarínicosInfo
- Publication number
- AR105593A1 AR105593A1 ARP160102378A ARP160102378A AR105593A1 AR 105593 A1 AR105593 A1 AR 105593A1 AR P160102378 A ARP160102378 A AR P160102378A AR P160102378 A ARP160102378 A AR P160102378A AR 105593 A1 AR105593 A1 AR 105593A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrocarbon group
- optionally substituted
- oxidized forms
- carbon atoms
- aromatic hydrocarbon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Reivindicación 1: Un compuesto de la formula (1), o una de sus sales, donde p es 1 ó 2; q es 0, 1 ó 2; r es 1 ó 2; s es 0 ó 1, donde el total de r y s es 1 ó 2; Q es CR¹R²NR⁵R⁶, NR⁵R⁶, OR⁷, SR⁷; R¹ se selecciona de hidrógeno o un grupo hidrocarbonado no aromático C₁₋₆ que está opcionalmente sustituido con uno a seis átomos de flúor y donde uno o dos, pero no todos los átomos de carbono del grupo hidrocarbonado puede estar opcionalmente reemplazado con un heteroátomo seleccionado de O, N y S y sus formas oxidadas; R² se selecciona de hidrógeno o un grupo hidrocarbonado no aromático C₁₋₆ que está opcionalmente sustituido con uno a seis átomos de flúor y donde uno o dos, pero no todos los átomos de carbono del grupo hidrocarbonado puede estar opcionalmente reemplazado con a heteroátomo seleccionado de O, N y S y sus formas oxidadas; R³ se selecciona de hidrógeno; flúor; ciano; hidroxi; amino; y un grupo hidrocarbonado no aromático C₁₋₆ que está opcionalmente sustituido con uno a seis átomos de flúor y donde uno, dos o tres, pero no todos, los átomos de carbono del grupo hidrocarbonado pueden estar opcionalmente reemplazados con un heteroátomo seleccionado de O, N y S y sus formas oxidadas; R⁴ es un hidrógeno o un grupo hidrocarbonado no aromático C₁₋₆ que esté opcionalmente sustituido con uno a seis átomos de flúor y donde uno o dos, pero no todos los átomos de carbono del grupo hidrocarbonado puede estar opcionalmente reemplazado con a heteroátomo seleccionado de O; N y S y sus formas oxidadas; R⁵ se selecciona de hidroxi; OR⁷; COR⁷; COOR⁷; CH₂COR⁷; CH₂COOR⁷; un grupo hidrocarbonado no aromático C₁₋₆ que está opcionalmente sustituido con uno a seis átomos de flúor y donde uno o dos, pero no todos, los átomos de carbono del grupo hidrocarbonado puede estar opcionalmente reemplazado con a heteroátomo seleccionado de O, N y S y sus formas oxidadas; y un grupo W o CH₂W donde el W es un anillo de 5 ó 6 miembros opcionalmente sustituido que contiene 0, 1, 2 ó 3 heteroátomos seleccionados de O, N y S y sus formas oxidadas; R⁶ se selecciona de hidroxi; OR⁷; COR⁷; COOR⁷; CH₂COR⁷; CH₂COOR⁷; un grupo hidrocarbonado no aromático C₁₋₆ que está opcionalmente sustituido con uno a seis átomos de flúor y donde uno o dos, pero no todos, los átomos de carbono del grupo hidrocarbonado puede estar opcionalmente reemplazado con a heteroátomo seleccionado de O, N y S y sus formas oxidadas; y un grupo W o CH₂W donde W es un anillo de 5 ó 6 miembros opcionalmente sustituido que contiene 0, 1, 2 ó 3 heteroátomos seleccionado de O, N y S y sus formas oxidadas; y R⁷ se selecciona de hidrógeno de un grupo hidrocarbonado no aromático C₁₋₆ que está opcionalmente sustituido con uno a seis átomos de flúor y donde uno o dos, pero no todos, los átomos de carbono del grupo hidrocarbonado puede estar opcionalmente reemplazado con a heteroátomo seleccionado de O, N y S y sus formas oxidadas; y un grupo W o CH₂W o grupo hidrocarbonado-W C₁₋₄ donde W es un anillo de 5 ó 6 miembros opcionalmente sustituido que contiene 0, 1, 2 ó 3 heteroátomos seleccionados de O, N y S y sus formas oxidadas; y la línea de puntos indica un segundo enlace carbono-carbono opcional, con la condición de que cuando un segundo enlace carbono-carbono está presente, entonces R³ esté ausente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1513742.5A GB201513742D0 (en) | 2015-08-03 | 2015-08-03 | Muscarinic agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105593A1 true AR105593A1 (es) | 2017-10-18 |
Family
ID=54063148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102378A AR105593A1 (es) | 2015-08-03 | 2016-08-03 | Agonistas muscarínicos |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9758506B2 (es) |
| EP (2) | EP3822262B1 (es) |
| JP (1) | JP6876675B2 (es) |
| KR (1) | KR102664558B1 (es) |
| CN (1) | CN107949558B (es) |
| AR (1) | AR105593A1 (es) |
| AU (1) | AU2016302048B2 (es) |
| BR (1) | BR112018002279B1 (es) |
| CA (1) | CA2993484C (es) |
| CL (1) | CL2018000292A1 (es) |
| CO (1) | CO2018002060A2 (es) |
| DK (1) | DK3331869T3 (es) |
| ES (1) | ES2850298T3 (es) |
| GB (1) | GB201513742D0 (es) |
| HK (1) | HK1250160A1 (es) |
| IL (1) | IL257064A (es) |
| MX (1) | MX2018001564A (es) |
| MY (1) | MY195244A (es) |
| PH (1) | PH12018500259A1 (es) |
| RU (1) | RU2737158C2 (es) |
| TW (1) | TWI723037B (es) |
| UA (1) | UA123315C2 (es) |
| WO (1) | WO2017021730A1 (es) |
| ZA (1) | ZA201800715B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2780015T3 (pl) | 2011-11-18 | 2017-06-30 | Heptares Therapeutics Limited | Agonisty receptora muskarynowego M1 |
| CN108026050B (zh) | 2015-08-03 | 2021-04-30 | 格兰马克药品股份有限公司 | 作为RORγ调节剂的新型化合物 |
| JP6955482B2 (ja) | 2015-08-03 | 2021-10-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆアルファの修飾因子として有用なヘテロ環化合物 |
| GB201513742D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| ES2789756T3 (es) | 2015-12-23 | 2020-10-26 | Merck Sharp & Dohme | Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4 |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| US20200369611A1 (en) * | 2017-08-01 | 2020-11-26 | Boehringer Ingelheim International Gmbh | Intermediate compounds and methods |
| WO2019079410A1 (en) | 2017-10-17 | 2019-04-25 | Vanderbilt University | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
| EP3732163A4 (en) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4 |
| HUE061533T2 (hu) * | 2018-03-23 | 2023-07-28 | Pfizer | Piperazin azaspiro származékok |
| GB201810239D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810245D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| JOP20220082A1 (ar) * | 2019-10-09 | 2023-01-30 | Novartis Ag | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 |
| US11485742B2 (en) | 2019-10-09 | 2022-11-01 | Novartis Ag | 2-azaspiro[3.4]octane derivatives as M4 agonists |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ570497A (en) * | 2006-02-22 | 2011-09-30 | Vertex Pharma | Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors |
| UY31672A1 (es) | 2008-02-28 | 2009-09-30 | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
| WO2011112825A2 (en) * | 2010-03-10 | 2011-09-15 | Vanderbilt University | Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same |
| PL2780015T3 (pl) * | 2011-11-18 | 2017-06-30 | Heptares Therapeutics Limited | Agonisty receptora muskarynowego M1 |
| SG11201501620QA (en) * | 2012-09-18 | 2015-04-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor agonists |
| SG11201606269WA (en) * | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
| JP6955482B2 (ja) | 2015-08-03 | 2021-10-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆアルファの修飾因子として有用なヘテロ環化合物 |
| CN108026050B (zh) | 2015-08-03 | 2021-04-30 | 格兰马克药品股份有限公司 | 作为RORγ调节剂的新型化合物 |
| GB201513742D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| AR105556A1 (es) | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | Derivados de etinilo |
-
2015
- 2015-08-03 GB GBGB1513742.5A patent/GB201513742D0/en not_active Ceased
-
2016
- 2016-08-03 MX MX2018001564A patent/MX2018001564A/es unknown
- 2016-08-03 CN CN201680043661.XA patent/CN107949558B/zh active Active
- 2016-08-03 AR ARP160102378A patent/AR105593A1/es unknown
- 2016-08-03 UA UAA201801267A patent/UA123315C2/uk unknown
- 2016-08-03 KR KR1020187006156A patent/KR102664558B1/ko active IP Right Grant
- 2016-08-03 EP EP20213929.1A patent/EP3822262B1/en active Active
- 2016-08-03 ES ES16750223T patent/ES2850298T3/es active Active
- 2016-08-03 JP JP2018504985A patent/JP6876675B2/ja active Active
- 2016-08-03 RU RU2018105020A patent/RU2737158C2/ru active
- 2016-08-03 AU AU2016302048A patent/AU2016302048B2/en active Active
- 2016-08-03 MY MYPI2018000148A patent/MY195244A/en unknown
- 2016-08-03 BR BR112018002279-9A patent/BR112018002279B1/pt active IP Right Grant
- 2016-08-03 EP EP16750223.6A patent/EP3331869B1/en active Active
- 2016-08-03 US US15/227,325 patent/US9758506B2/en active Active
- 2016-08-03 WO PCT/GB2016/052386 patent/WO2017021730A1/en active Application Filing
- 2016-08-03 TW TW105124670A patent/TWI723037B/zh active
- 2016-08-03 CA CA2993484A patent/CA2993484C/en active Active
- 2016-08-03 DK DK16750223.6T patent/DK3331869T3/da active
-
2017
- 2017-09-08 US US15/699,674 patent/US10351545B2/en active Active
-
2018
- 2018-01-21 IL IL257064A patent/IL257064A/en unknown
- 2018-02-01 CL CL2018000292A patent/CL2018000292A1/es unknown
- 2018-02-01 US US15/886,057 patent/US10167272B2/en active Active
- 2018-02-02 ZA ZA2018/00715A patent/ZA201800715B/en unknown
- 2018-02-02 PH PH12018500259A patent/PH12018500259A1/en unknown
- 2018-02-26 CO CONC2018/0002060A patent/CO2018002060A2/es unknown
- 2018-07-24 HK HK18109575.4A patent/HK1250160A1/zh unknown
-
2019
- 2019-05-21 US US16/418,354 patent/US11091456B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105593A1 (es) | Agonistas muscarínicos | |
| CL2020003260A1 (es) | Compuestos de naftiridinona sustituidos útiles como activadores de células t | |
| CL2018002928A1 (es) | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| SV2016005328A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| CL2019000542A1 (es) | Compuestos de tetraciclina y métodos de uso de los mismos. | |
| AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| UY37367A (es) | Nuevos compuestos para uso en el tratamiento de una infección viral y composiciones de los mismos | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| NI201400099A (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CR20160578A (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona | |
| AR084277A1 (es) | Compuestos utiles para el tratamiento del sida | |
| CL2015002222A1 (es) | Compuestos de azabencimidazol como inhibidores de isoenzimas pde4 para el tratamiento del snc y otros trastornos. | |
| AR107738A1 (es) | Amidas de ácido n-(5-halógen-1,3,4-oxadiazol-2-il)arilcarboxílico y su uso como herbicidas | |
| CO2019002692A2 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5. | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
| CO2018010787A2 (es) | Compuesto de griseofulvina | |
| CL2020000139A1 (es) | Moduladores de lxr que contienen amina o (tio)amida. | |
| AR086492A1 (es) | Procedimientos e intermediarios para preparar agentes anti-hiv |